A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer

Status: Recruiting
Phase: Phase 2
Diagnosis: Breast: Early Stage Disease
NCT ID: NCT01617668 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-331


To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in women with triple negative breast cancer whose tumors are positive for a defined pattern of gene expression


Conducting Institutions:
Massachusetts General Hospital

Overall PI:
Aditya Bardia MD, MPH, Massachusetts General Hospital

Site-responsible Investigators:

Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Histologically confirmed diagnosis of invasive triple negative breast cancer - Known status for the LCL161 predictive gene expression signature as determined during molecular pre-screening - Candidates for mastectomy or breast-conserving surgery - Primary tumor of greater than 20 mm and less than 50 mm diameter measured by imaging - Regional nodes N0-N2 - Absence of distant metastatic disease - ECOG performance status 0-1 - Adequate bone marrow function - Adequate liver function and serum transaminases - Adequate renal function Exclusion Criteria: - Bilateral or inflammatory breast cancer (bilateral mammography is required during Screening/baseline); locally recurrent breast cancer - Patients currently receiving systemic therapy for any other malignancy, or having received systemic therapy for a malignancy in the preceding 3 months - Uncontrolled cardiac disease - Patients who are currently receiving chronic treatment (>3 months) with corticosteroids at a dose ≥ 10 mg of prednisone (or its glucocorticoid equivalent) per day (inhaled and topical steroids are allowed), or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug - Impaired GI function that may affect the absorption of LCL161 - Pregnant or breast feeding (lactating) women - Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 180 days after study treatment - Other protocol-defined inclusion/exclusion criteria may apply
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Request Appointment Online